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Abstract
Objective: Platelet activation in COPD patients is associated with an increased risk
of cardiovascular events. We aimed at assessing the mean platelet volume (MPV),
as an index of platelet activation, in COPD patients both when stable or during acute
exacerbation (AE).
Research design and methods: 478 patients (75 with AE) and 72 age-matched
healthy controls were enrolled. Medical history, co-morbidities, medications, pulmo‐
nary function tests, MPV and blood cell count, erythrocyte sedimentation rate (ERS)
and C reactive protein (CRP) were recorded.
Results: MPV was higher in COPD than in controls (8.7 ± 1.1 fL and 8.4 ± 0.8 fL respectively, p = 0.025) and increased
across the severity of the diseases as assessed by post bronchodilator FEV1 categorized I to IV (p > 0.05). MPV was higher
in COPD patients during AE as compared with stable condition (8.7 ± 1.0 fL and 8.9 ± 1.0 fL, p = 0.021).
MPV ≥ 10.5 fL correlated with the presence of at least one co-existing cardiovascular disease (p = 0.008) . No correlation
was observed between MPV and CRP or ERS in patients or in controls. A negative correlation was found between platelet
count and MPV in COPD patients taken together.
Limitations: The retrospective design did not allow to assess a clear cause-effect relationship between MPV and all the
pathophysiological factors considered
Conclusions: Elevated MPV is associated with lower platelet count and with cardiovascular co-morbidity in COPD patients.
MPV value is higher in the more severe COPD and during AE. Present findings warrant future studies to confirm a possible
clinically relevant role for platelet activation on cardiovascular risk in the population of COPD.
   
Just Accepted by Current Medical Research and Opinion
© 2016 Taylor & Francis. This provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
DISCLAIMER: The ideas and opinions expressed in the journal's Just Accepted articles do not necessarily reflect those of Taylor & Francis (the Publisher),
the Editors or the journal. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising from or related to
any use of the material contained in these articles. The reader is advised to check the appropriate medical literature and the product information currently
provided by the manufacturer of each drug to be administered to verify the dosages, the method and duration of administration, and contraindications. It is
the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to
determine drug dosages and the best treatment for the patient. Just Accepted articles have undergone full scientific review but none of the additional editorial
preparation, such as copyediting, typesetting, and proofreading, as have articles published in the traditional manner. There may, therefore, be errors in
Just Accepted articles that will be corrected in the final print and final online version of the article. Any use of the Just Accepted articles is subject to the
express understanding that the papers have not yet gone through the full quality control process prior to publication.
 ORIGINAL ARTICLE 
PLATELET ACTIVATION AND CARDIOVASCULAR CO-MORBIDITIES IN PATIENTS 
WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
Malerba Mario
1
, Olivini Alessia
1
, Radaeli Alessandro
2
, Ricciardolo Fabio Luigi Massimo
3
, Clini 
Enrico
4
  
 
1 Department of Internal Medicine, University of Brescia and AOU Spedali Civili, Brescia, Italy 
2 Department of Emergency AOU Spedali Civili, Brescia, Italy  
3 Department of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, 
Orbassano, Italy. 
4 Department of Medical and Surgical Sciences, Ospedale Villa Pineta, University of Modena-
Reggio Emilia, Modena, Italy. 
 
Address for correspondence: Mario Malerba, Department of Internal Medicine, University of 
Brescia and AOU Spedali Civili, Brescia, Italy. Tel: +39 030 3995250; mario.malerba@unibs.it 
 
Key words: mean platelet volume, COPD, cardiovascular co-morbidities, platelet, inflammation. 
[Short title: MPV and cardiovascular co-morbidity in COPD]   
JU
ST
 AC
CE
PT
ED
 ABSTRACT  
Objective: Platelet activation in COPD patients is associated with an increased risk of 
cardiovascular events. We aimed at assessing the mean platelet volume (MPV), as an index of 
platelet activation, in COPD patients both when stable or during acute exacerbation (AE). 
Research design and methods: 478 patients (75 with AE) and 72 age-matched healthy controls were 
enrolled. Medical history, co-morbidities, medications, pulmonary function tests, MPV and blood 
cell count, erythrocyte sedimentation rate (ERS) and C reactive protein (CRP) were recorded. 
Results: MPV was higher in COPD than in controls (8.7 ± 1.1 fL and 8.4 ± 0.8 fL respectively, p = 
0.025) and increased across the severity of the diseases as assessed by post bronchodilator FEV1 
categorized I to IV (p>0.05). MPV was higher in COPD patients during AE as compared with 
stable condition (8.7 ± 1.0 fL and 8.9 ± 1.0 fL, p = 0.021).  
MPV ≥ 10.5 fL correlated with the presence of at least one co-existing cardiovascular disease (p = 
0.008) . No correlation was observed between MPV and CRP or ERS in patients or in controls. A 
negative correlation was found between platelet count and MPV in COPD patients taken together. 
Limitations: The retrospective design did not allow to assess a clear cause-effect relationship 
between MPV and all the  pathophysiological factors considered  
Conclusions: Elevated MPV is associated with lower platelet count and with cardiovascular co-
morbidity in COPD patients. MPV value is higher in the more severe COPD and during AE. 
Present findings warrant future studies to confirm a possible clinically relevant role for platelet 
activation on cardiovascular risk in the population of COPD.  
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 INTRODUCTION 
An important association was observed between chronic obstructive pulmonary disease (COPD) 
and cardiovascular diseases [1,2], being events such as myocardial infarction [3] and stroke [4] 
more frequent in these patients than in the healthy population. Indeed, both COPD and 
cardiovascular diseases share common risk factors, smoking habit as most important [5]. 
A large body of research aimed at finding the explanation of this enhanced risk in the COPD 
population, focusing in particular on systemic inflammation as a driving mechanism for 
atherothrombosis [6, 7].  Recent studies have shown the presence of increased platelet activation in 
patients with COPD [8-10], which may be correlated with the presence of circulating inflammatory 
mediators and with the hypoxemia which is typical in the advanced stages of the disease [11]. The 
increased mean platelet volume (MPV) is an index of accelerated platelet activation, derives from 
the change of the platelets’ shape, and leads to enhanced thrombosis [12-13]. Very recently, it has 
been demonstrated that high MPV is correlated with higher risk of developing atherosclerotic 
thrombotic cardiovascular events, mainly in chronic patients suffering from diabetes, hypertension 
and obesity, where platelet activation is enhanced [14]. Moreover, in elderly male patients with 
COPD, the MVP was inversely correlated with the level of FEV1, and the impairment of 
cardiopulmonary function [15]. 
In the present study we aimed at assessing the MPV value in a large population of COPD patients 
both when stable or during an episode of acute exacerbation (AE) and to determine whether 
correlation exists between MPV and the stage of disease severity, the systemic inflammation and 
the increased prevalence of atherothrombotic cardiovascular events in the studied population.   JU
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 METHODS  
Study protocol  
Four-hundred and seventy eight COPD patients admitted between April 2012 and December 2013, 
for different purposes (poorly controlled arterial hypertension, syncope, pleuritic chest pain, 
dizziness and disequilibrium, associated-disease disability), at both the Unit of Internal Medicine-
Spedali Civili (Brescia), Rehabilitation Unit-Ospedale Villa Pineta (Pavullo n/F, MO), and 
Pneumology Unit- Ospedale San Luigi (Orbassano, TO) were retrospectively studied. Seventy-five 
of them were admitted due to an AE of the disease. 
Diagnosis of COPD was based on the medical history and confirmed by spirometry performed 
during the first day following hospitalization [16], or when reaching stability at discharge in those 
subjects having exacerbation.  
Patients were classified by severity in four stages according to the post bronchodilator FEV1 as 
follows: Stage I= FEV1 ≥ 80% pred, Stage II FEV1= 50-79% pred, Stage III FEV1= 30-49%pred, 
Stage IV FEV1< 30%pred [16] (Table 1). AE has been defined according to the international 
consensus [17]. Clinical stability was defined as the absence of significant changes in symptoms 
beyond the expected daily variation, along with no requirements for any increase in usual 
treatments [18]. 
Control population consisted of 72 subjects matched for age, sex and smoking history, but with 
normal pulmonary functions, similarly referred to our units.  
Subjects with bronchial asthma, acute and/or chronic pulmonary thrombo-embolism, obstructive 
sleep apnea, connective tissue and inflammatory bowel diseases, fever of any origin, chronic renal 
failure, chronic liver diseases, haematological abnormalities, or unable to perform spirometry were 
excluded. 
This study complied with the Declaration of Helsinki and was approved by the local Review Board 
at each centre. A waiver of consent was granted, and patient identity was protected. 
Measurements 
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 Medical history, respiratory function tests, and blood analysis was recorded in each participant. 
Active smoking was defined if a current use of >2 cigarettes/day was reported; the number of 
pack/year was also recorded. 
Respiratory Function Tests- Lung spirometry was performed in accordance with the standard 
procedure [19]. Forced Vital Capacity (FVC) and Forced Expiratory Volume in the first second 
(FEV1) were recorded. 
Peripheral Blood analysis- Blood sample was taken at admission. Ten millilitres of fasting bloods 
were drawn from each subject enrolled, tubes containing the dipotassium salt of thylenediamine 
tetraacetic acid (EDTA) were used for measurement of MPV [20]. Samples were immediately taken 
to the Hospital central laboratory to be analysed. 
Total count on platelets, red and white cell, the MPV, and the level of both erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) were recorded for study purposes. The 
inter- and intra-assays coefficients of variation of these assays were below 5%. 
Co-morbidities- Co-existing chronic diseases were identified by examining the clinical 
documentation provided by each subject at admission and/or by the results from diagnostic tests 
performed during hospitalization.  
Diabetes mellitus was diagnosed if plasma glucose > 126 mg/dL, and/or treatment with anti-
diabetic drugs, and/or presence of haemoglobin A1c > 6.5% [21, 22]. 
Systemic arterial hypertension was defined if assuming antihypertensive treatment, in the presence 
of a medical history with documented high blood pressure (BP), if systolic BP >140 mm Hg and/or 
diastolic BP > 90 mm Hg were recorded on 3 separate occasions [23].  
Dyslipidemia was defined in the presence of hypolipidemic treatment, and if total cholesterol >200 
mg/dL, and/or triglycerides >200 mg/dL, high-density lipoprotein cholesterol >40 mg/dL, low-
density lipoprotein cholesterol >130 mg/dL [24].   
Coronary artery disease was based on the history of previously documented myocardial infarction 
and/or suggestive changes at the electrocardiogram (ECG) [25].  
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 Heart failure was defined according to the medical history and the presence of documented left 
ventricular ejection fraction <55% (Simpson method) together with some degree of exertional 
dyspnea [26]. 
Obesity was defined when BMI was greater than or equal to 30.  
The presence of cerebrovascular disease was based on the past medical history of cerebral 
infarction, cerebral thrombosis, transient ischemic attack, artery occlusion at the carotid or vertebral 
vessels. 
Statistical Analysis 
Data were presented as mean ± standard deviation (SD). Subjects were analysed according to 
different groups (stable or exacerbated COPD and Controls) or categories (presence of at least one 
cardiovascular co-morbidity, MPV value ≥10.5 fL as the median cut-off of distribution). 
After verifying that data were normally distributed, group comparisons were performed using t-test 
for independent variables. Analysis of correlation among variables was performed by linear 
regression with a straight trend and through the calculation of Pearson coefficient. Categorical 
variables were compared by the chi-square test method.  
A p value <0.05 was considered to be significant. All analysed were performed with a dedicated 
software (SPSS 21.0 for Windows; SPSS, Chicago, IL).  
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 RESULTS 
Characteristics of subjects in study are displayed in Table 1. Most of the COPD patients were in 
stage II or III according to the post bronchodilator FEV1. Seventy-five patients were under AE, 
being twenty-five (33%) of them in stage IV of the disease. 
Chronic co-morbidities were similar between COPD and controls, as well as the use of 
antiaggregants and/or anticoagulants was similar. 
Two-hundred twenty seven (47.4%) out of the 478 COPD patients (192/403 stable and 35/75 during 
AE) had at least one cardiovascular disease (hypertension, acute myocardial infarction, exertional 
angina, coronary artery disease, cerebral vascular disease, arterial disease of the lower limbs, 
thromboembolic disease). The proportion of patients with at least one cardiovascular co-morbidity 
was also similar (48.6%) in the control group. 
Two-hundred fifty eight COPD were taking acetylsalicylic acid (ASA) as an antiplatelet therapy (11 
subjects were under dual antiplatelet therapy with ASA and clopidogrel); 89 patients were receiving 
anticoagulation therapy with warfarin (n=86) or enoxaparin (n=3). Forty-one out of 72 controls 
were receiving ASA (one subject was under dual therapy with ASA and clopidogrel), while 11 were 
assuming warfarin. No difference was noted in the medication taken in the group of COPD patients 
under AE compared to the group of COPD patients in stable condition. 
Table 2 resumes data of both lung function and peripheral blood in the study groups. In particular, 
the mean MPV differed significantly between COPD patients taken together and controls 
(respectively 8.7 ± 1.1 fL and 8.4 ± 0.8 fL in COPD patients and in controls p = 0.025), despite 
platelet count was similar. The mean values of ESR and PCR were similar in patients and in 
controls (see Table 2).  
Noteworthy, we observed an inverse correlation between the platelets count and the MPV in 
patients with COPD (Pearson = -0.115, p <0.05, Figure 1) but not in controls (Pearson = -0.009, ns). 
Mean MPV did not correlate with ESR, PCR, the total number of co-morbidities and the use of 
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 antiplatelet/anticoagulant therapies in the whole population in study, nor in the COPD group either 
when stable or during AE. 
Sub-group analysis: COPD patients without or with AE. 
Table 3 and Figure 2 show comparison of mean MPV value between study groups including COPD 
with or without AE. In COPD patients, MPV level was lower when stable as compared during AE 
(8.7 ± 1.0 fL, and 8.9 ± 1.0 fL respectively, p = 0.021). Moreover, MPV was higher in COPD stage 
II to IV when compared with stage I (see Table 3 and Figure3). Mean MPV was also compared 
within each post bronchodilator category in stable patients and in those under AE, but no significant 
differences were reported. Among the COPD patients, neither ESR nor PCR differed according to 
the different clinical condition (stable state or AE). 
Platelet count was lower during AE than in stable state (211.2 ± 96.5 and 218.7 ± 64.2 x 103 / mm3 
respectively, p<0.05). 
Finally, the presence of a MPV ≥10.5 fL significantly correlated with the presence of at least one 
cardiovascular co-morbidity in COPD patients taken together (but not in controls) (see Table 4).  
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 DISCUSSION 
Our study shows that MPV values are higher in COPD patients than in healthy controls and 
increases with the degree of severity and during AE. Moreover, high level of MPV is associated 
with at least one cardiovascular co-morbidity in the population of COPD but not in comparable 
controls.  
Data of mean MPV in COPD are still inconsistent and contradictory. Onder et al. [27] observed for 
the first time higher MPV values in hypoxic COPD patients when compared with controls. 
Additionally, Bansal et al. [28] as well as Ulasli et al [29] reported higher MPV in patients with 
COPD. The latter study also measured a reduced MPV during AE,  however the smoking status of 
patients was not reported and COPD patients had a significantly lower BMI, at difference with our 
study.  
A recent paper [30] has evaluated 269 COPD patients and finding have shown that, in disagreement 
with our data, lower MPV during AE negatively correlated with PCR values. This  discrepancy is 
probably due to different characteristics between the two populations studied, furthermore neither 
BMI nor smoking history were reported and lung function (FEV1 and FEV1/FVC) was surprisingly 
similar both in stable and exacerbated COPD patients.  
Cui et al [15] was the first to observe that increased MPV in very old male patients with COPD was 
associated with impaired cardiopulmonary function, linking the concept of platelet activation with 
the prevalence of cardiovascular co-morbidities  in this population. Recent awareness on the 
enhanced risk of cardiovascular co-morbidities in COPD patients has stimulated research to study 
the possible pathophysiological mechanisms that stand behind this phenomenon [31]. Several 
mechanisms including hypoxia, systemic inflammation and imbalance of the proteases to 
antiproteases ratio (with an increased expression of neutrophil elastase) have been considered able 
to promote platelet activation and hyperaggregability and to stimulate atheromasic plaque 
progression [8-11]. The mechanism of platelet activation involves different phenomena such as 
change in the shape of platelets, increase in the MPV, expression of P-selectin in the cell’s 
JU
ST
 AC
CE
PT
ED
 membrane [32], formation of aggregates with platelets and monocytes [33], thus favouring the 
endothelial activation and the atherosclerotic plaque formation. 
The increased values of MPV could follow the hypoxemia that is typical in patients with COPD, in 
particular at peripheral tissue level, which may trigger bone marrow stimulation or increase the 
sequestration of smaller platelets [28]. COPD is associated with  systemic inflammation, oxidative 
stress, activation of circulating inflammatory cells and increased levels of inflammatory mediators, 
mechanisms that may be partly responsible of platelet activation as observed in COPD [29,31], 
where the presence of a pro-thrombotic state with high production of thrombin and pro-coagulative 
mediators was reported [34]. 
By confirming previous data on increased MPV in the COPD population, present study is the first 
to show that it is present in the more severe stages of the disease and/or during AE. Therefore, the 
severity of COPD is possibly associated with a progressive increase of MPV, despite the 
pathophysiological mechanism(s) involved, among all those mentioned above, has not yet been 
completely clarified. Indeed, our data do not suggest a direct relationship between hypoxemia and 
elevation of MPV, neither demonstrated a significant difference of inflammatory serum markers 
(ESR and CRP) between COPD and controls. Notwithstanding, values of both CRP and ESR are 
higher in the two groups compared to the normal range. 
Interestingly, we have found a significant negative correlation between platelet count and MPV 
value only among the COPD population. This could be explained by the increased proportion of 
activated platelets sequestered at the peripheral level and by the precipitation of the latter in the 
form of aggregates of platelets and monocytes, which are typically seen during the process of 
platelet activation [35,36]. One of the most interesting and novel aspect of our study is the 
observation of a direct association between high MPV level (above the pre-defined limit of ≥10.5 
fL) and the at least one cardiovascular co-morbidity in patients with COPD but not in the controls.  
This finding could support the above mentioned hypothesis about the presence of a tight 
relationship between platelet activation, systemic atherosclerosis, plaque rupture and cardiovascular 
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 events in COPD patients. In a large population cohort (the “Rotterdam Study”) it has been recently 
demonstrated a higher prevalence of carotid atherosclerosis in elderly COPD compared with 
healthy controls, which is independent on the stage of the disease [37]. This study also advanced the 
concrete hypothesis that COPD may be an independent predictor for the presence of carotid 
atherosclerosis.  
Despite our findings in a consistent population of COPD confirm the role of platelet activation in 
the disease and also clarify the concept that this happens according to the degree of severity and 
during AE, present study has some limitations that deserves to be outlined. A first potential limit is 
the retrospective design, thus a selection bias (e.g. the similar systemic inflammation level in both 
groups) may have occurred. Second, we were not able to report a patent cause-effect relationship 
between variable of interest (MPV) and all the pathophysiological factors behind (such as arterial 
oxygen pressure level). Notwithstanding, the strong point of our study is primarily the large sample 
size of COPD patients and the objective recording of co-morbidities [38].  
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 CONCLUSION 
Our observational study underlines the presence of platelet activation (i.e. elevated MPV and reduce 
platelet count) in COPD patients, being patients with higher degree of severity an/or those under 
AE at higher risk of developing cardiovascular co-morbidity. This indirectly suggests a clear 
relationship between platelet activation and the excess of cardiovascular events commonly observed 
in the COPD population. On the basis of the present data it would be possible to hypothesize the 
prophylactic use of antiplatelets or anticoagulants in order to reduce the future risk of 
cardiovascular events [39] in patients with COPD, especially when severe or frequent exacerbators. 
To test this hypothesis, however, further prospective studies on larger populations are needed. 
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 FIGURE LEGENDS 
Figure 1: Relationship between MPV and Platelet count in COPD patients.  
Figure 2: Comparison between MPV in controls vs stable COPD vs COPD with exacerbation. 
(horizontal black lines show the means, boxes show values between 25 and 75%, vertical black 
lines show maximum and minimum values). 
Figure 3: Comparison between MPV in COPD Stage I vs COPD Stage II, III and IV. (horizontal 
black lines show the means, boxes show values between 25 and 75%, vertical black lines show 
maximum and minimum values). 
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 Table 1: Demographic and clinical characteristics of the subjects studied. 
  
 COPD COPD 
stable 
COPD 
exacerbation 
Controls p 
Total number 478 403 75 72  
Age years, mean ± SD 74.26 ± 7.8 74.26 ± 7.8 74.26 ± 7.8 75.83 ± 9.19 N.S. 
SEX, % of Male 62% 64% 60% 60% N. S. 
BMI, kg/m2 27.17 ± 4.51 28.47 ± 3.61 26.87 ± 5.51 27.75 ±  5.2 N. S. 
Smoking status, % 
       Yes 
       No 
       Former 
Packs/year, mean ± SD 
 
32% 
18% 
50% 
40.82 ± 25.23 
 
30% 
20% 
51% 
38.43 ± 33.21 
 
32% 
18% 
50% 
40.23 ± 43.21 
 
 
31% 
20% 
49% 
39.72 ± 18.58 
 
N.S. 
N.S. 
N.S. 
N.S. 
Patients with acute exacerbation  75 (18.6%) 0 75 -  
Disease Severity, n/% 
Stage I (FEV1≥80%pred) 
 Stage II (FEV1=50-79% pred) 
 Stage III (FEV1=30-49% pred) 
 Stage IV (FEV1<30% pred) 
 
50       (10.5%) 
175     (36.6%) 
165     (34.5%) 
88       (18.4%) 
 
36 (8,9%) 
156 (38,7%) 
148 (36,7%) 
63 (15,6%) 
 
 
14 (18,7) 
19 (25,3%) 
17 (22,7%) 
25 (33,3%) 
 
 
- 
- 
- 
- 
 
Co-morbidities, n/% 
       Diabetes 
       Dyslipidemia 
       Arterial Hypertension 
       Obesity 
       Myocardial infarction, angina, coronaroscl. 
       Cerebrovascular disease 
       Heart failure  
       Other cardiovascular diseases  
143 (30%) 
86 (18%) 
282 (59%) 
52 (11%) 
162 (34%) 
158 (33%) 
258 (54%) 
124 (26%) 
118 (29%) 
72 (18%) 
231 (57%) 
44 (11%) 
135 (33%) 
132 (33%) 
219 (54%) 
105 (26%) 
25(33%) 
14 (19%) 
51 (68%) 
8 (10%) 
27 (36%) 
26 (34%) 
39 (52%) 
19 (25%) 
23 (32%) 
15 (21%) 
45 (63%) 
5 (7%) 
20 (29%) 
21 (30%) 
34 (47%) 
17 (24%) 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
Medication, n/%  
Antiaggregation 
       ASA 
       Clopidogrel 
 
258 (54%) 
11 (2%) 
 
219(54%) 
9(2%) 
 
39(52%) 
2(2%) 
 
41 (57%) 
1 (1%) 
 
N.S. 
N.S. 
Anticoagulation 
       Warfarin sodico 
       Enoxaparina 
 
86 (18%) 
3 (1%) 
 
73(18) 
3(1%) 
 
13(17) 
0 
 
11 (15%) 
0 (0%) 
 
N.S. 
N.S. 
Inhaled drugs 
       Anticholinergics 
       β2-agonists 
       Corticosteroids 
       Oxygen 
 
 
224 (47%) 
200 (42%) 
230 (48%) 
33 (7%) 
 
190(47%) 
170(42%) 
195(48%) 
28(7%) 
 
34(45%) 
30(40%) 
35(46%) 
5(6%) 
 
- 
- 
- 
- 
 
 
COPD: chronic obstructive pulmonary disease. BMI: body mass index. FEV1: Forced expiratory volume at first second. ASA: acid 
acetylsalicylic.  
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 Table 2. Lung function and peripheral blood analysis of the subjects studied. 
 COPD COPD 
stable 
COPD 
exacerbation 
Controls p 
Functional data    
FEV1 (% pred.) 47.4 ± 18.32 48.6±16.9 26.3±16.9 98 ± 1.2 p < 0.001 
FVC (% pred.) 71.6±21 73.0±19.0 37.4±33 90.2 ± 14.3 p < 0.001 
Tiffenau index 51.0±10.1 51.2±10.3 56.2±18.3 93.2± 4.5 p < 0.001 
Laboratory data    
White Blood Cells (x103/mm3) 9.05 ± 21.32 9.6 ± 26.2 10.6 ± 31.2 7.55 ± 14.58 p < 0.01 
Red Blood Cells (x106/mm3) 3.98 ± 0.23 3.7 ± 0.33 3.99 ± 0.26 3.81 ± 0.48 N.S. 
Platelets (x103/mm3) 215.2 ± 80.6 218.7 ± 64.2 211.2 ± 96.5 229.5 ± 61.6 p<0.05 
Mean Platelet Volume (MPV) (fL) 8.76 ± 1.08 8.7 ± 1.0 8.9 ± 1.0 8.44 ± 0.78 p < 0.05 
ESR (mm/h)  31.3 ± 67.1 32.3 ± 66.1 29.3 ± 50.3 28.4 ± 83.44 N.S. 
CRP (mg/l) 43.2 ± 153.2 46.2 ± 144 42.2 ± 156 46.5 ± 145.8 N.S. 
COPD: chronic obstructive pulmonary disease, FEV1: forced exhaled volume at first second, FVC: forced vital capacity, ESR: 
Erythrocyte Sedimentation Rate, CRP: C Reactive Protein. 
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 Table 3. Statistical comparison of MPV in the study groups and within the COPD population. 
 MPV (fL) p 
COPD 8.7 ± 1.1 
0.025 
Controls 8.4 ± 0.8 
COPD stable 8.7 ± 1.0 
0.021 
COPD with exacerbation 8.9 ± 1.0 
Stage I(FEV1≥80% pred) 8.3 ± 0.9 
0.011* 
Stage II (FEV1=50-79% pred) 8.7 ± 0.8 
Stage III(FEV1=30-49% pred) 9.1 ± 1.5 
Stage IV(FEV1<30% pred) 8.8 ± 1.0 
Data expressed as mean ± standard deviation 
COPD: chronic obstructive pulmonary disease, MPV: mean platelet volume 
*ANOVA 
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